Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMESBW)

• Drug Name: PMID20005102C1 Drug Info
• Synonyms: GTPL8181; BDBM50305878; B99

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 46225540
  TTD Drug ID: DMMESBW

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphoinositide dependent protein kinase-1 (PDPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AR-12	DM4RK6P	Lymphoma	2A80-2A86	Phase 1	[2]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[3]
BX-912	DMZA45C	Discovery agent	N.A.	Investigative	[4]
BX-795	DMRIMLJ	Discovery agent	N.A.	Investigative	[4]
PHT-427	DMI96Y3	Discovery agent	N.A.	Investigative	[5]
PF-5177624	DMUOFT0	Solid tumour/cancer	2A00-2F9Z	Investigative	[6]
GSK-2334470	DM3BI7R	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]

Drug(s) Targeting PAK-1 protein kinase (PAK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RKI-1447	DMGTAWC	Discovery agent	N.A.	Investigative	[8]
Il-94	DMPNQ27	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[10]
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[10]
GDC-0068	DMWBZJD	Breast cancer	2C60-2C65	Phase 3	[10]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[11]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[12]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[13]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[14]
RX-0201	DMTBAV3	Pancreatic cancer	2C10	Phase 2	[15]
PTX-200	DM0ZIT2	Breast cancer	2C60-2C65	Phase 2	[10]
Triciribine prodrug	DMBN1XS	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[14]

Drug(s) Targeting RAC-gamma serine/threonine-protein kinase (AKT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[16]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[2]
MK-2206	DMT1OZ6	Rectal adenocarcinoma	2B92	Phase 2	[17]
GSK2141795	DMSHE70	Colorectal cancer	2B91.Z	Phase 2	[18]
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
LYS-6KAKT1	DMLXGAI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
LY2780301	DM93AJW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
XL418	DME0F5W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]
SR13668	DMO5760	Solid tumour/cancer	2A00-2F9Z	Phase 1	[22]
TCN-P	DMV0AH8	Acute myeloid leukaemia	2A60	Phase 1	[23]

Drug(s) Targeting Fungal Protein kinase A (Fung ypkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[24]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[25]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[26]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[27]
PMID19364658C33	DMSE1C3	Discovery agent	N.A.	Investigative	[28]
BX-912	DMZA45C	Discovery agent	N.A.	Investigative	[4]
BX-795	DMRIMLJ	Discovery agent	N.A.	Investigative	[4]
chelerythrine	DMCP1G9	Discovery agent	N.A.	Investigative	[29]
PMID21742770C1	DME3JMH	Discovery agent	N.A.	Investigative	[30]
Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS)	DM1JWGH	Discovery agent	N.A.	Investigative	[31]

Drug(s) Targeting Ribosomal protein S6 kinase beta-1 (S6K1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
NNI-362	DMPCV65	Alzheimer disease	8A20	Phase 1	[32]
PF-4708671	DMO0892	Ulcerative colitis	DD71	Clinical trial	[33]
PMID27410995-Compound-Figure3c	DMDQMZT	N. A.	N. A.	Patented	[34]
Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1	DM6O2Q9	N. A.	N. A.	Patented	[34]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[35]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[25]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[36]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[35]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[35]

Drug(s) Targeting RAC-beta serine/threonine-protein kinase (AKT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Akt inhibitor VIII	DMDVIT1	Discovery agent	N.A.	Investigative	[37]
PHT-427	DMI96Y3	Discovery agent	N.A.	Investigative	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fungal Protein kinase A (Fung ypkA)	TTYVI76	Q56921_YEREN	Inhibitor	[1]
PAK-1 protein kinase (PAK1)	TTFN95D	PAK1_HUMAN	Inhibitor	[1]
Phosphoinositide dependent protein kinase-1 (PDPK1)	TT9QBI6	PDPK1_HUMAN	Inhibitor	[1]
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Inhibitor	[1]
RAC-beta serine/threonine-protein kinase (AKT2)	TTH24WI	AKT2_HUMAN	Inhibitor	[1]
RAC-gamma serine/threonine-protein kinase (AKT3)	TTAZ05C	AKT3_HUMAN	Inhibitor	[1]
Ribosomal protein S6 kinase beta-1 (S6K1)	TTG0U4H	KS6B1_HUMAN	Inhibitor	[1]

References

• [1] 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [4] Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
• [5] Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17.
• [6] Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402.
• [7] Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene. 2014 Aug 21;33(34):4330-9.
• [8] Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
• [9] PAK1: A Therapeutic Target for Cancer Treatment. ACS Med Chem Lett. 2013 Mar 19;4(5):431-2.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [12] Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [15] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [16] The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5.
• [17] First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95.
• [18] Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7.
• [19] DOI: 10.1016/S1359-6349(10)71767-5
• [20] A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
• [21] Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
• [22] Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53.
• [23] Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Invest New Drugs.2011 Dec;29(6):1381-9.
• [24] Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address
• [25] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [26] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694).
• [28] Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
• [29] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [30] A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
• [31] Inhibition of protein kinase A activity interferes with long-term, but not short-term, memory of conditioned taste aversions. Behav Neurosci. 2002 Dec;116(6):1070-4.
• [32] Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease. Stem Cell Res Ther. 2021 Jan 13;12(1):59.
• [33] Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
• [34] Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
• [35] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [36] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [37] Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4.